Recently, a phase 1, open-label, dose-escalation, and dose-expansion study of AZD3759 showed promising efficacy of AZD3759 in EGFR-mutated NSCLC patients with CNS metastases [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.